Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 18/20 | 0.84 |
| ▸ | FYN | P06241 | 2/20 | 0.70 |
| ▸ | BTK | Q06187 | 1/20 | 0.55 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.54 |
| ▸ | SRC | P12931 | 7/20 | 0.53 |
| ▸ | TEK | Q02763 | 7/20 | 0.53 |
| ▸ | KDR | P35968 | 2/20 | 0.50 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.50 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6430670 | 0.94 | LCK (0.85) | LCKFYNBTKRIPK1SRC | |
| SCHEMBL6430677 | 0.92 | LCK (0.89) | LCKFYNBTKRIPK1SRC | |
| SCHEMBL14268434 | 0.92 | LCK (0.88) | LCKFYNBTKRIPK1SRC | |
| SCHEMBL6430474 | 0.92 | LCK (1.00) | LCKFYNBTKRIPK1SRC | |
| SCHEMBL6435233 | 0.89 | LCK (0.90) | LCKFYNBTKRIPK1SRC | |
| SCHEMBL6431663 | 0.89 | LCK (0.81) | LCKFYNBTKSRCTEK | |
| SCHEMBL6433956 | 0.89 | LCK (0.87) | LCKFYNBTKRIPK1SRC | |
| SCHEMBL6430648 | 0.89 | LCK (0.89) | LCKFYNBTKRIPK1SRC | |
| SCHEMBL6434171 | 0.89 | LCK (0.89) | LCKFYNBTKRIPK1SRC | |
| SCHEMBL4826601 | 0.89 | LCK (0.82) | LCKFYNBTKRIPK1SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6921763-B2 | Pyrazolopyrimidines as therapeutic agents | ABBOTT LABORATORIES (US) | 2005-07-26 | — | — | US | disclosed |
| US-20050008640-A1 | Method of treating transplant rejection | ABBOTT LABORATORIES | 2005-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050008640-A1 | Method of treating transplant rejection | LCK, ZAP70, FYN | LCK 1/4885FYN 3/4885BTK 42/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.